Dror Bashan
2022
In 2022, Dror Bashan earned a total compensation of $1.5M as President and Chief Executive Officer at Protalix BioTherapeutics, a 27% increase compared to previous year.
Compensation breakdown
Option Awards | $177,564 |
---|---|
Salary | $359,972 |
Stock Awards | $817,576 |
Other | $113,184 |
Total | $1,468,296 |
Bashan received $817.6K in stock awards, accounting for 56% of the total pay in 2022.
Bashan also received $177.6K in option awards, $360K in salary and $113.2K in other compensation.
Rankings
In 2022, Dror Bashan's compensation ranked 2,267th out of 5,760 executives tracked by ExecPay. In other words, Bashan earned more than 60.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,267 out of 5,760 | 61st |
Division Manufacturing | 1,228 out of 3,136 | 61st |
Major group Chemicals And Allied Products | 542 out of 1,422 | 62nd |
Industry group Drugs | 497 out of 1,323 | 62nd |
Industry Biological Products, Except Diagnostic Substances | 119 out of 291 | 59th |
Source: SEC filing on May 18, 2023.
Bashan's colleagues
We found two more compensation records of executives who worked with Dror Bashan at Protalix BioTherapeutics in 2022.
News
Protalix BioTherapeutics CEO Dror Bashan's 2023 pay jumps 83% to $2.7M
April 29, 2024
Protalix BioTherapeutics CEO Dror Bashan's 2022 pay jumps 27% to $1.5M
May 18, 2023
Protalix BioTherapeutics CEO Dror Bashan's 2021 pay slips 14% to $1.2M
April 29, 2022
Protalix BioTherapeutics CEO Moshe Manor's 2019 pay slips 14% to $616K
April 15, 2020